Integrating New Data on HIV Adverse Events From IAS 2023: Pharmacist Perspectives

In this episode, Brooke Bates, PharmD, BCPS, AAHIVP, and Neha Sheth Pandit, PharmD, AAHIVP, BCPS, discuss the most clinically relevant studies on HIV adverse events presented at IAS 2023, including: REPRIEVE study of pitavastatin for cardiovascular prevention in people living with HIV at low to moderate cardiovascular riskData on weight change with switch from integrase inhibitor–based ART to doravirine/islatravir in the P017 and P018 studiesDEFINE study evaluating weight change after a switch to DRV/COBI/FTC/TAF in people living with HIV who experienced weight gain with integrase inhibitor–based ARTFaculty: Brooke Bates, PharmD, BCPS, AAHIVPSpecialty Pharmacy Clinical Manager Pediatric HIV Clinical PharmacistIndiana University HealthIndianapolis, IndianaNeha Sheth Pandit, PharmD, AAHIVP, BCPSProfessorVice Chair for Research and ScholarshipDepartment of Practice, Sciences, and Health Outcomes ResearchSchool of PharmacyUniversity of Maryland Clinical PharmacistTHRIVE ProgramBaltimore, MarylandLink to full program: https://bit.ly/3ZjSFhg Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There are no comments yet.

Please log in to write the first comment.